Neutralization of ocular surface TNF-α reduces ocular surface and lacrimal gland inflammation induced by in vivo dry eye

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 12, 2013, Pages 7557-7566

  Ji, Yong Woo ^a   Byun, Yu Jeong ^a   Choi, Wungrak ^a   Jeong, Eunae ^a   Kim, Jin Sun ^a   Noh, Haemi ^a   Kim, Eun Sun ^b   Song, Yun Jung ^b   Park, Seung Kook ^b   Lee, Hyung Keun ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Hanall Biopharma   (South Korea)

Author keywords

Cytokines; Dry eye; Lacrimal gland; Tumor necrosis factor

Indexed keywords

CYTOKINE; ETANERCEPT; GAMMA INTERFERON; HL 036; INTERLEUKIN 21; INTERLEUKIN 6; SCOPOLAMINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DENSITY; CELL VIABILITY; CONTROLLED STUDY; CORNEA EROSION; CYTOTOXICITY; DRY EYE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; KINETICS; LACRIMAL GLAND DISEASE; MOUSE; NONHUMAN; OCULAR SURFACE DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE; TUMOR NECROSIS FACTOR RECEPTOR 1 GENE;

CYTOKINES; DRY EYE; LACRIMAL GLAND; TUMOR NECROSIS FACTOR-Α;

ANIMALS; CELL COUNT; CORNEA; CYTOKINES; DACRYOCYSTITIS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GOBLET CELLS; IMMUNOGLOBULIN G; KERATITIS; KERATOCONJUNCTIVITIS SICCA; LACRIMAL APPARATUS; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887846278     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11515     Document Type: Article

References (36)

1. Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. Arch Ophthalmol. 2009; 127: 763-768.
2. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998; 17: 584-589.
3. Brignole F, Pisella PJ, Goldschild M, De Saint Jean M, Goguel A, Baudouin C. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci. 2000; 41: 1356-1363.
4. Massingale ML, Li X, Vallabhajosyula M, Chen D, Wei Y, Asbell PA. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea. 2009; 28: 1023-1027.
5. Barabino S, Montaldo E, Solignani F, Valente C, Mingari MC, Rolando M. Immune response in the conjunctival epithelium of patients with dry eye. Exp Eye Res. 2010; 91: 524-529.
6. De Paiva CS, Villarreal AL, Corrales RM, et al. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. Invest Ophthalmol Vis Sci. 2007; 48: 2553-2560.
7. Zheng X, de Paiva CS, Li DQ, Farley WJ, Pflugfelder SC. Desiccating stress promotion of Th17 differentiation by ocular surface tissues through a dendritic cell-mediated pathway. Invest Ophthalmol Vis Sci. 2010; 51: 3083-3091.
8. Roescher N, Tak PP, Illei GG. Cytokines in Sjogren's syndrome: potential therapeutic targets. Ann Rheum Dis. 2010; 69: 945-948.
9. Boehm N, Riechardt AI, Wiegand M, Pfeiffer N, Grus FH. Proinflammatory cytokine profiling of tears from dry eye patients by means of antibody microarrays. Invest Ophthalmol Vis Sci. 2011; 52: 7725-7730.
10. Lam H, Bleiden L, de Paiva CS, Farley W, Stern ME, Pflugfelder SC. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol. 2009; 147: 198-205. e1.
11. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003; 3: 745-756.
12. Cope AP, Londei M, Chu NR, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest. 1994; 94: 749-760.
13. Braun J, Sieper J. Biological therapies in the spondyloarthritides-the current state. Rheumatology (Oxford). 2004; 43: 1072-1084.
14. Ma HL, Napierata L, Stedman N, et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 2010; 62: 430-440.
15. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876-885.
16. Miceli-Richard C, Dieude P, Hachulla E, Puechal X, Cornelis F, Mariette X. Tumour necrosis factor receptor 2 (TNFRSF1B) association study in Sjogren's syndrome. Ann Rheum Dis. 2007; 66: 1684-1685.
17. Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjogren's syndrome: one-year followup. Arthritis Rheum. 2002; 46: 3301-3303.
18. Pessler F, Monash B, Rettig P, Forbes B, Kreiger PA, Cron RQ. Sjogren syndrome in a child: favorable response of the arthritis to TNFalpha blockade. Clin Rheumatol. 2006; 25: 746-748.
19. Moutsopoulos NM, Katsifis GE, Angelov N, et al. Lack of efficacy of etanercept in Sjogren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis. 2008; 67: 1437-1443.
20. Park CY, Zhuang W, Lekhanont K, et al. Lacrimal gland inflammatory cytokine gene expression in the botulinum toxin B-induced murine dry eye model. Mol Vis. 2007; 13: 2222-2232.
21. Yoon KC, Jeong IY, Park YG, Yang SY. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea. 2007; 26: 431-437.
22. Barabino S, Shen L, Chen L, Rashid S, Rolando M, Dana MR. The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci. 2005; 46: 2766-2771.
23. Bron AJ. Diagnosis of dry eye. Surv Ophthalmol. 2001; 45(suppl 2): S221-S226.
24. Shim J, Park C, Lee HS, et al. Change in prostaglandin expression levels and synthesizing activities in dry eye disease. Ophthalmology. 2012; 119: 2211-2219.
25. Lee HK, Ryu IH, Seo KY, Hong S, Kim HC, Kim EK. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology. 2006; 113: 198-205.
26. Lee HK, Lee KS, Kim HC, Lee SH, Kim EK. Nerve growth factor concentration and implications in photorefractive keratectomy vs laser in situ keratomileusis. Am J Ophthalmol. 2005; 139: 965-971.
27. Stern ME, Gao J, Siemasko KF, Beuerman RW, Pflugfelder SC. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004; 78: 409-416.
28. Cope AP, Liblau RS, Yang XD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med. 1997; 185: 1573-1584.
29. Fox RI, Stern M, Michelson P. Update in Sjogren syndrome. Curr Opin Rheumatol. 2000; 12: 391-398.
30. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebocontrolled pilot clinical trial. Arthritis Rheum. 2004; 50: 2240-2245.
31. Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X. Treatment of primary Sjogren syndrome: a systematic review. JAMA. 2010; 304: 452-460.
32. Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol. 2002; 72: 856-863.
33. Kang KY, Kim HO, Kwok SK, et al. Impact of interleukin-21 in the pathogenesis of primary Sjogren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther. 2011; 13: R179.
34. Scofield RH. IL-21 and Sjogren's syndrome (Editorial). Arthritis Res Ther. 2011; 13: 137.
35. Kang EH, Lee YJ, Hyon JY, Yun PY, Song YW. Salivary cytokine profiles in primary Sjogren's syndrome differ from those in non-Sjogren sicca in terms of TNF-alpha levels and Th-1/Th-2 ratios. Clin Exp Rheumatol. 2011; 29: 970-976.
36. Li Z, Choi W, Oh HJ, Yoon KC. Effectiveness of topical infliximab in a mouse model of experimental dry eye. Cornea. 2012; 31(suppl 1): S25-S31.